JP2020511494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511494A5 JP2020511494A5 JP2019551608A JP2019551608A JP2020511494A5 JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5 JP 2019551608 A JP2019551608 A JP 2019551608A JP 2019551608 A JP2019551608 A JP 2019551608A JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- composition
- natriuretic peptide
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 83
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 26
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 26
- 239000000692 natriuretic peptide Substances 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 7
- 239000004475 Arginine Chemical group 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 230000009723 vascular congestion Effects 0.000 claims description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 4
- 101000749809 Homo sapiens 2',3'-cyclic-nucleotide 3'-phosphodiesterase Proteins 0.000 claims description 4
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 claims description 4
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 claims description 4
- 101000796277 Homo sapiens C-type natriuretic peptide Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 125000001924 fatty-acyl group Chemical group 0.000 claims description 4
- 102000047974 human CNP Human genes 0.000 claims description 4
- 230000001452 natriuretic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 5
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022070710A JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| US62/475,147 | 2017-03-22 | ||
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Division JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511494A JP2020511494A (ja) | 2020-04-16 |
| JP2020511494A5 true JP2020511494A5 (enExample) | 2021-04-01 |
| JP7126270B2 JP7126270B2 (ja) | 2022-08-26 |
Family
ID=63585777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551608A Active JP7126270B2 (ja) | 2017-03-22 | 2018-03-21 | Ｎｐｒａアゴニスト、組成物およびその使用 |
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (enExample) |
| EP (1) | EP3601314A4 (enExample) |
| JP (2) | JP7126270B2 (enExample) |
| KR (1) | KR102714599B1 (enExample) |
| CN (1) | CN110603260B (enExample) |
| AU (2) | AU2018239352A1 (enExample) |
| BR (1) | BR112019019720A2 (enExample) |
| CA (1) | CA3056433A1 (enExample) |
| EA (1) | EA201992226A1 (enExample) |
| IL (1) | IL269388B2 (enExample) |
| MX (1) | MX2019010960A (enExample) |
| MY (1) | MY201165A (enExample) |
| PH (1) | PH12019550163A1 (enExample) |
| SG (1) | SG11201908580XA (enExample) |
| WO (1) | WO2018175534A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972590A4 (en) * | 2019-05-22 | 2023-06-14 | Merck Sharp & Dohme LLC | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES |
| US20220281886A1 (en) | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20230416328A1 (en) * | 2020-06-12 | 2023-12-28 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury |
| IL298992A (en) * | 2020-06-12 | 2023-02-01 | Pharmain Corp | C-type natriuretic peptides and their methods for cancer treatment |
| CN120435308A (zh) | 2022-10-21 | 2025-08-05 | 伊莱利利公司 | 长效利尿钠肽及其用途 |
| AR130935A1 (es) | 2022-11-02 | 2025-02-05 | Novo Nordisk As | Compuestos de cnp |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| DE60331584D1 (de) * | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| BRPI0815416A2 (pt) * | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| BRPI0904622A2 (pt) * | 2008-05-23 | 2016-06-21 | Asubio Pharma Co Ltd | peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma |
| HRP20161739T1 (hr) * | 2009-05-20 | 2017-03-10 | Biomarin Pharmaceutical Inc. | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2678025B1 (en) * | 2011-02-23 | 2017-03-08 | Madeleine Pharmaceuticals Pty Ltd | Vsdl for use in the treatment of acute decompensated congestive heart failure |
| US20120220528A1 (en) * | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en not_active Ceased
- 2018-03-21 MY MYPI2019005393A patent/MY201165A/en unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en not_active Abandoned
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 KR KR1020197031122A patent/KR102714599B1/ko active Active
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 IL IL269388A patent/IL269388B2/en unknown
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201270A patent/AU2025201270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511494A5 (enExample) | ||
| US8603969B2 (en) | Pancreatic polypeptide family motifs and polypeptides comprising the same | |
| JP4173914B2 (ja) | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 | |
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2017518303A5 (enExample) | ||
| JP2014521684A5 (enExample) | ||
| MX2014012625A (es) | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. | |
| AU2020200934B2 (en) | Long-acting adrenomedullin derivative | |
| JP7126270B2 (ja) | Ｎｐｒａアゴニスト、組成物およびその使用 | |
| PH12022551651A1 (en) | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTS | |
| EP3681529A1 (en) | Mic-1 and glp-1 for use in the treatment of obesity | |
| JP5687266B2 (ja) | 大動脈線維症の治療のための組成物および方法 | |
| US20190290721A1 (en) | Combination | |
| WO2022054825A1 (ja) | ウイルス性感染症を有する対象における症状又は障害を予防又は治療するための医薬 | |
| TH1901005876A (th) | ตัวทำการ npra, องค์ประกอบและการใช้สิ่งดังกล่าว | |
| WO2016144968A1 (en) | Relaxin therapy for disorders of the diaphragm | |
| JP3034032B2 (ja) | 腸疾患用薬剤 | |
| JPWO2021094259A5 (enExample) | ||
| HK40088755A (zh) | Hbv和hdv感染的联合治疗 | |
| HK40017696B (zh) | Npra激动剂、组合物及其用途 | |
| Morine et al. | Neutralizing Endoglin Activity Rescues Maladaptive Remodeling in Heart Failure | |
| WO2009080608A1 (en) | Y2 receptor agonists |